12 Scopus citations

Abstract

Purpose: Stereotactic body radiotherapy (SBRT) is an attractive treatment option for patients with metastatic and/or unresectable tumors, however its use is limited to smaller tumors. Lattice is a form of spatially fractionated radiotherapy that may allow safe delivery of ablative doses to bulky tumors. We previously described Lattice SBRT, which delivers 20 Gy in 5 fractions with a simultaneous integrated boost to 66.7 Gy in a defined geometric arrangement (Lattice boost). The goal of this study was to prospectively evaluate the acute toxicity and quality of life (QoL) of patients with large tumors (>5 cm) treated with Lattice SBRT. Methods: This was a single-arm phase I trial conducted between October 2019 and August 2020. Patients with tumors > 4.5 cm were eligible. Lattice SBRT was delivered every other day. The primary outcome was the rate of 90-day treatment-associated (probably or definitely attributable) grade 3 + acute toxicity by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 criteria. Other outcomes included changes in patient reported toxicity and QoL inventories, GTV, and peripheral blood cytokines. Results: Twenty patients (22 tumors) were enrolled. Median GTV was 579.2 cc (range: 54.2–3713.5 cc) in volume and 11.1 cm (range: 5.6–21.4 cm) in greatest axial diameter. Fifty percent of tumors were in the thorax, 45% abdomen/pelvis, and 5% extremity. There was no likely treatment-associated grade 3 + toxicity in the 90-day period (acute and sub-acute). There was one case of grade 4 toxicity possibly associated with Lattice SBRT. Conclusions: This phase I study met its primary endpoint of physician reported short-term safety. An ongoing phase II clinical trial of Lattice SBRT will evaluate late safety and efficacy of this novel technique.

Original languageEnglish
Pages (from-to)317-322
Number of pages6
JournalRadiotherapy and Oncology
Volume167
DOIs
StatePublished - Feb 2022

Keywords

  • Clinical tiral
  • Large tumors
  • Palliative
  • SBRT
  • Safety
  • Spatially fractionated radiotherapy

Fingerprint

Dive into the research topics of 'LITE SABR M1: A phase I trial of Lattice stereotactic body radiotherapy for large tumors'. Together they form a unique fingerprint.

Cite this